Hybrid liposomes showing enhanced accumulation in tumors as theranostic agents in the orthotopic graft model mouse of colorectal cancer

Liposomes have been attracted considerable attention as phospholipid spherical vesicles, over the past 40 years. These lipid vesicles are valued in biomedical application due to their ability to carry both hydrophobic and hydrophilic agents, high biocompatibility and biodegradability. Various methods have been used for the synthesis of liposomes, so far and numerous modifications have been performed to introduce liposomes with different characteristics like surface charge, size, number of their layers, and length of circulation in biological fluids. This article provides an overview of the significant advances in synthesis of liposomes via active or passive drug loading methods, as well as describes some strategies developed to fabricate their targeted formulations to overcome limitations of the "first-generation" liposomes.

show abstract

“…A number of successful results have been obtained from passive targeting property of liposomes in cancer therapy. 133 - 138…”

Section: Liposomes As Targeting Nanocarriersmentioning

confidence: 99%

What We Need to Know about Liposomes as Drug Nanocarriers: An Updated Review

Abbasi¹,

Kouchak²,

Mirveis³

et al. 2022

Adv Pharm Bull

View full text Add to dashboard Cite

show abstract

“…26,55,56,57,58,59,6 Immunocompetent and immunodeficient mice with xenografted tumors are traditionally transplanted subcutaneously or orthotopically. 61,62 These models are widely used due to their availability, low cost, and ability to mimic attributes of human malignancies by recapitulating neoplastic cell architecture and conserving genetic and phenotypic biology at the histological and molecular models. 55 This makes PDX models the favored method of identifying drugs that significantly inhibit tumor growth, validating tumor biomarkers, and predicting treatment outcomes.…”

Section: In Vivo Modelsmentioning

confidence: 99%

Cancer Models to Defeat Therapy Resistance in Pancreatic Ductal Adenocarcinoma

2021

Spring 2021

View full text Add to dashboard Cite

One of the largest hurdles to the efficacy of cancer therapeutics, and a main cause of relapse, is therapy resistance. In response, researchers have developed model systems to better understand therapy resistance. Cancer research employs several model systems that reflect the biology of actual human tumors: in vitro models (2D, 3D cell cultures), in vivo models (PDX, GEMMS, transgenic), proteomic models, and computational or mathematical models. One cancer that has been extensively modeled is pancreatic ductal adenocarcinoma (PDAC). PDAC is the third most common cause of annual cancer deaths in developed countries; as its incidence and mortality rates continue to increase, PDAC is projected to be the second leading cause of cancer deaths by 2030. Although chemotherapy is a pillar of clinical PDAC treatment, its outcome typically leads to multi-drug resistance, drastically restricting the curative effect of drugs for a variety of tumors. Elucidating the underlying mechanisms for resistance through different models is essential for the development of new strategies and therapies. This review provides insight into the range of in vitro and in vivo models of pancreatic cancer used in preclinical research. This paper provides an overview of platforms for cancer research with a focus on those devoted to resistance mechanisms in PDAC and to the primary therapeutic intervention for PDAC, gemcitabine (GEM).

show abstract

“…[9][10][11] Despite advancements in treatment methods to cope with the adverse effects of chemotherapy, these methods still have drawbacks towards the comfort and needs of chemotherapy patients. [12][13][14] Other therapies, such as surgical resection, can be complicated by massive bleeding and other side effects. 6 Radiotherapy risks patients of having skin toxicity, pelvic fractures and infertility.…”

Section: Introductionmentioning

confidence: 99%

The Plausible Use of Mango (Mangifera indica) Peel Isoquercitrin as Adjuvant Therapy for Colorectal Cancer: Translating Research from Bench to Bedside

Habiburrahman

Sutopo

Rahadiani

2023

InaJGHE

View full text Add to dashboard Cite

A deadly and debilitating disease, colorectal cancer (CRC), is rapidly becoming a significant threat to public health. However, current therapeutic approaches are still hampered by various side effects. Due to its benefits and remarkable apoptotic impact on cancer cells, plant-derived flavonoids now garner interest as candidates for cancer therapy. Isoquercitrin, a flavonoid commonly found in fruit plants, especially mangoes, is notable due to its ability to inhibit cancer development through various mechanisms. This review aims to highlight the use of isoquercitrin extracted from mango peels in inhibiting CRC carcinogenesis. A literature search was done on Pubmed, Proquest, and Google Scholar using inclusion and exclusion criteria, and a narrative review was synthesised using the evidence gathered. Validity assessment was done through the the Office of Health Assessment and Translation (OHAT) and Oxford Center for Evidence-Based Medicine (CEBM) critical assessment tools. Evidence suggested that isoquercitrin is promising as adjuvant therapy in CRC. It may inhibit overaccumulation of cytoplasmic β-catenin and its translocation into the nucleus, thus downregulating the expression of target proto-oncogenes leading to carcinogenesis of colon crypts. Isoquercitrin concentration in mango peel is abundant, 557.7 mg/kg in dried mango peel and 31.0 mg/kg in pure extracts. A pharmacology study approved that a daily intake of 5.4 mg/kgBW of isoquercitrin has an effective anticancer effect. This substance has good oral bioavailability and is well-tolerated but inhibits the metabolising enzymes CYP1A1 and CYP1B1. In conclusion, isoquercitrin is a potential adjuvant in inhibiting CRC growth with minimum costs and side effects.

show abstract

Hybrid liposomes showing enhanced accumulation in tumors as theranostic agents in the orthotopic graft model mouse of colorectal cancer

Cited by 11 publications

References 31 publications

What We Need to Know about Liposomes as Drug Nanocarriers: An Updated Review

What We Need to Know about Liposomes as Drug Nanocarriers: An Updated Review

Cancer Models to Defeat Therapy Resistance in Pancreatic Ductal Adenocarcinoma

The Plausible Use of Mango (Mangifera indica) Peel Isoquercitrin as Adjuvant Therapy for Colorectal Cancer: Translating Research from Bench to Bedside

Contact Info

Product

Resources

About